Also known as: gene and cell therapies
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Precision medicine is transforming healthcare through genetic testing and AI integration, with research showing direct-to-consumer testing identifies unknown health risks and drives medical action. However, reimbursement systems lag behind scientific advances, creating barriers to widespread adoption of personalized treatment approaches.
The FDA issued reforms on January 11, 2026, loosening chemistry, manufacturing, and control requirements for cell and gene therapy products to advance innovation and accommodate the unique complexity of these treatments.
